Loading your workspace…
All markets
FDA moves BPC-157 to Category 1 by…?
Foretrace AI research
Understand the odds. Examine the reasoning.
Polymarket shows market prices. Foretrace adds AI probability estimates, opposing evidence and a price-dependent outcome or pass decision for each open market.
Choose a market to analyze 1 open question · Evidence required
24h volumeUnavailable
Total volume$4.8K
Liquidity$84.6
Event end date · UTCJan 1, 2027
Price history
Market probabilityLoading price history…
Polymarket · UTC
Sampled market observations, not AI forecasts. Lines connect available observations. Legend values are current provider quotes; chart points may be older.
Outcomes & resolution rules
2 marketsThese are market-implied probabilities, not AI forecasts. A displayed quote may differ from the price available for your order.
August 31, 2026ClosedMarket odds0%
Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by August 31, 2026?
Yes0%Polymarket estimate
No100%Polymarket estimate
- Liquidity
- Unavailable
- Deadline · UTC
- Sep 1, 2026
- Yes bid / ask
- — / 0.1¢
- Trading fees
- Enabled · verify on Polymarket
Closed market · historical data
This market is closed. Its historical data remains available.
How research worksResolution rules
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.